Turning Point Therapeutics, Inc. (NASDAQ:TPTX) received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for its lead drug candidate Repotrectinib in Patients With One Prior ROS1 Tyrosine Kinase Inhibitor and no Prior Chemotherapy.
The designation grant was supported by efficacy analyses of 50 patients pooled from the Phase 1 and Phase 2 portions of the TRIDENT-1 study.
